Socioeconomic Burden of Ovarian Cancer in 11 Countries
Open accessAbstract
PURPOSE: Ovarian cancer remains among the most aggressive tumors with the lowest survival probability. Projections are that ovarian cancer will claim more than 8 million lives between 2022 and 2050 without better prevention or control measures. METHODS: We built an Excel-based instrument that uses a prevalence-based cost-of-illness approach and a societal perspective to estimate the burden of ovarian cancer. The instrument leverages data from editions of the World Ovarian Cancer Coalition's Every Woman Study, contains a micro-costing framework to assess the resources and costs of providing care, and uses data from novel systematic reviews and meta-analyses conducted to estimate the effect of ovarian cancer on patient labor productivity outcomes and the time caregivers devote to caring for people living with the disease. RESULTS: Across 11 countries, we estimated US dollars 70 billion in socioeconomic losses attributable to ovarian cancer. Health expenditures to cover treatment in the first 2 years after diagnosis were 7, 41, and 118 times total health spending per capita in high-, upper-middle-, and low- and lower-middle countries, respectively. Patients spent 3,663 years traveling to or receiving treatment. Women lost labor productivity equivalent to 2.5 million workdays due to ill-health from ovarian cancer, and 9,403 women living with ovarian cancer or survivors were estimated to be missing from the workforce. Caregivers spent 17,112 person-years providing practical support to patients—an average of 33 days per woman living with ovarian cancer. CONCLUSION: This study is the first to quantify the social and economic burden of ovarian cancer in 11 countries and highlights its significant cost and defines actions needed to improve ovarian cancer outcomes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hutchinson et al estimated across 11 counties that patients with ovarian cancer receive an average of 800 hours of unpaid care per year.
“Hutchinson et al 6 estimated across 11 counties that patients with ovarian cancer receive an average of 800 hours of unpaid care per year.”
From Systematic Review and Meta-Analyses of Time-Use, Productivity, and Labor Outcomes Among Unpaid Cancer Caregivers (2026) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33326-3 · Cited by 6,145 · see citing works
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492 · see citing works
US Health Care Spending by Payer and Health Condition, 1996-2016
Dieleman, J. L., Cao, J., Chapin, A., Chen, C., Li, Z., Liu, A., Horst, C., Kaldjian, A., Matyasz, T., Scott, K. W., et al. (2020) · JAMA · doi:10.1001/jama.2020.0734 · Cited by 1,313 · see citing works
Economic burden of cancer across the European Union: a population-based cost analysis
Luengo-Fernández, R., Leal, J., Gray, A. M., & Sullivan, R. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70442-x · Cited by 1,010 · see citing works
Chen, S., Cao, Z. L., Klaus Prettner, A., Kühn, M., Yang, J., Jiao, L., Wang, Z., Li, W., Geldsetzer, P., Bärnighausen, T., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7826 · Cited by 915 · see citing works
Financial Hardships Experienced by Cancer Survivors: A Systematic Review
Altice, C. K., Banegas, M. P., Tucker-Seeley, R. D., & Yabroff, K. R. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw205 · Cited by 864 · see citing works
Cost-of-illness studies: concepts, scopes, and methods
Jo, C. (2014) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2014.20.4.327 · Cited by 800 · see citing works
Menon, U., Gentry-Maharaj, A., Burnell, M., Singh, N., Ryan, A., Karpinskyj, C., Carlino, G., Taylor, J., Massingham, S. K., Raikou, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00731-5 · Cited by 730 · see citing works
Global access to surgical care: a modelling study
Alkire, B. C., Raykar, N. P., Shrime, M. G., Weiser, T. G., Bickler, S. W., Rose, J., Nutt, C. T., Greenberg, S. L. M., Kotagal, M., Riesel, J. N., et al. (2015) · The Lancet Global Health · doi:10.1016/s2214-109x(15)70115-4 · Cited by 688 · see citing works
Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation
Finch, A., Lubiński, J., Møller, P., Singer, C. F., Karlan, B. Y., Senter, L. A., Rosen, B. P., Mæhle, L., Ghadirian, P., Cybulski, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2820 · Cited by 665 · see citing works
Interventions to enhance return-to-work for cancer patients
de Boer, A. G. E. M., Taskila, T. K., Tamminga, S. J., Feuerstein, M., Frings‐Dresen, M. H. W., & Verbeek, J. H. A. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007569.pub3 · Cited by 430 · see citing works
Time costs associated with informal caregiving for cancer survivors
Yabroff, K. R., & Kim, Y. (2009) · Cancer · doi:10.1002/cncr.24588 · Cited by 303 · see citing works
Risk Factors for Ovarian Cancer: An Overview with Emphasis on Hormonal Factors
Salehi, F., Dunfield, L., Phillips, K. P., Krewski, D., & Vanderhyden, B. (2008) · Journal of Toxicology and Environmental Health. Part B, Critical Reviews · doi:10.1080/10937400701876095 · Cited by 201 · see citing works
Women, power, and cancer: a Lancet Commission
Ginsburg, O., Vanderpuye, V. D. N. K., Beddoe, A. M., Bhoo‐Pathy, N., Bray, F., Caduff, C., Florez, N., Fadhil, I., Hammad, N., Heidari, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01701-4 · Cited by 176 · see citing works
Self-citationA global comparison of the cost of patented cancer drugs in relation to global differences in wealth
Goldstein, D. A., Clark, J., Tu, Y., Zhang, J., Fang, F., Goldstein, R., Stemmer, S. M., & Rosenbaum, E. (2017) · Oncotarget · doi:10.18632/oncotarget.17742 · Cited by 155 · see citing works
Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes
Tozzi, R., Köhler, C., Ferrara, A., & Schneider, A. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.01.004 · Cited by 146 · see citing works
Matz, M., Coleman, M. P., Carreira, H., Salmerón, D., Chirlaque, M. D., Allemani, C., Bouzbid, S., Hamdi-Chérif, M., Zaidi, Z., Bah, E., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.11.019 · Cited by 140 · see citing works
Reference Case Guidelines for Benefit-Cost Analysis in Global Health and DevelopmentPreprint
Robinson, L. A., Hammitt, J. K., Cecchini, M., Chalkidou, K., Claxton, K., Cropper, M. L., Eozenou, P., de Ferranti, D., Deolalikar, A. B., Aguiar, F. C. G. D., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.4015886 · Cited by 121 · see citing works
Increased healthcare costs by later stage cancer diagnosis
McGarvey, N. H., Gitlin, M. D., Fadli, E., & Chung, K. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08457-6 · Cited by 116 · see citing works
Interventions to enhance return-to-work for cancer patients
de Boer, A. G. E. M., Taskila, T. K., Tamminga, S. J., Frings‐Dresen, M. H. W., Feuerstein, M., & Verbeek, J. H. A. M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007569.pub2 · Cited by 114 · see citing works
Interventions to improve outcomes for caregivers of patients with advanced cancer: a meta-analysis
Chow, R., Mathews, J. J., Cheng, E. Y., Lo, S., Wong, J., Alam, S., Hannon, B., Rodin, G., Nissim, R., Hales, S., et al. (2023) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djad075 · Cited by 98 · see citing works
Addressing Transportation Insecurity Among Patients With Cancer
Graboyes, E. M., Chaiyachati, K. H., Gall, J. S., Johnson, W., Krishnan, J. A., McManus, S. S., Thompson, L., Shulman, L. N., & Yabroff, K. R. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac134 · Cited by 97 · see citing works
Reid, F., Bhatla, N., Oza, A. M., Blank, S. V., Cohen, R., Adams, T. S., Benites, A., Gardiner, D., Gregory, S., Suzuki, M., et al. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000983 · Cited by 92 · see citing works
Self-citationChemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
Hashiguchi, Y., Kasai, M., Fukuda, T., Ichimura, T., Yasui, T., & Sumi, T. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000279 · Cited by 65 · see citing works
Algeo, N., Bennett, K., & Connolly, D. (2021) · BMC Cancer · doi:10.1186/s12885-021-08613-x · Cited by 53 · see citing works
Indicators of survival duration in ovarian cancer and implications for aggressiveness of care
von Gruenigen, V., Daly, B. J., Gibbons, H. E., Hutchins, J., & Green, A. (2008) · Cancer · doi:10.1002/cncr.23391 · Cited by 52 · see citing works
Ralaidovy, A. H., Gopalappa, C., Ilbawi, A., Pretorius, C., & Lauer, J. A. (2018) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-018-0157-0 · Cited by 49 · see citing works
Self-citationCost of Care for the Initial Management of Ovarian Cancer
Bercow, A. S., Chen, L., Chatterjee, S., Tergas, A. I., Hou, J. Y., Burke, W. M., Ananth, C. V., Neugut, A. I., Hershman, D. L., & Wright, J. D. (2017) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002317 · Cited by 45 · see citing works
Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer
Laskey, R. A., Poniewierski, M. S., Lopez, M. A., Hanna, R. K., Secord, A. A., Gehrig, P. A., Lyman, G. H., & Havrilesky, L. J. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.03.015 · Cited by 42 · see citing works
Next steps in the early detection of ovarian cancer
Bast, R. C., Han, C. Y., Lü, Z., & Lu, K. H. (2021) · Communications Medicine · doi:10.1038/s43856-021-00037-9 · Cited by 31 · see citing works
Wang, S., Wang, J., Kang, H., Zeng, L., Liu, G., Qiu, Y., & Wei, M. (2023) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2023.102489 · Cited by 30 · see citing works
Choi, Y., Terry, M. B., & Briollais, L. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2040 · Cited by 30 · see citing works
Economic Burden of Gynecological Cancers in Iran
Sargazi, N., Daroudi, R., Zendehdel, K., Hashemi, F. A., Tahmasebi, M., Darrudi, A., & Nahvijou, A. (2021) · Value in Health Regional Issues · doi:10.1016/j.vhri.2021.02.005 · Cited by 28 · see citing works
Numico, G., Zanelli, C., Ippoliti, R., Rossi, M., Traverso, E. S., Antonuzzo, A., & Bellini, R. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.08.023 · Cited by 27 · see citing works
The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study
Delgado-Ortega, L., Domínguez, A. G., Borràs, J. M., Oliva, J., González-Haba, E., Menjón, S., Perez, P. G.-R., Vicente, D., Cordero, L., Jiménez, M., et al. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-018-0986-y · Cited by 21 · see citing works
A micro costing of NHS cancer genetic services
Griffith, G. L., Edwards, R. T., Gray, J., Butler, R., Wilkinson, C., Turner, J., France, B., & Bennett, P. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602270 · Cited by 21 · see citing works
Hurry, M. V., Hassan, S., Seung, S. J., Walton, R., Elnoursi, A., & McGee, J. (2021) · Journal of health economics and outcomes research · doi:10.36469/jheor.2021.29145 · Cited by 20 · see citing works
Algera, M. D., Morton, R. H., Sundar, S. S., Farrell, R., van Driel, W. J., Brennan, D. J., Rijken, M. J., Sfeir, S., Allen, L., Eiken, M., et al. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-004563 · Cited by 14 · see citing works
Pickwell‐Smith, B., Greenley, S. L., Lind, M., & Macleod, U. (2023) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2023.100458 · Cited by 9 · see citing works
Tone, A. A., Boghosian, T., Ross, A., Baugh, E., Altman, A. D., Dawson, L. M., Reid, F., & Crawford, C. (2022) · Current Oncology · doi:10.3390/curroncol29050271 · Cited by 8 · see citing works
Self-citationHe, T., Li, H., & Zhang, Z. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01173-7 · Cited by 7 · see citing works
Quality of life of family caregivers of people with cancer in palliative care.
Holguín, E. D. S. A., Arias‐Rojas, M., & Carreño-Moreno, S. (2021) · PubMed · doi:10.1590/s1980-220x2020015103740 · Cited by 5 · see citing works
Health services costs for ovarian cancer in Australia: Estimates from the 45 and Up Study
Goldsbury, D. E., Vassallo, A. J., Weber, M. F., Steinberg, J., Webb, P. M., DeFazio, A., & Canfell, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282851 · Cited by 5 · see citing works
Societal costs of ovarian cancer in a population-based cohort – a cost of illness analysis
Palmqvist, C., Persson, J., Albertsson, P., Dahm‐Kähler, P., & Johansson, M. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2140015 · Cited by 3 · see citing works
Noll, F., Adams, T. S., Cohen, S. R., Soerjomataram, I., & Reid, F. (2022) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003449 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Reid F, Adams T, Adel RS, et al: Every Woman Study LMIC edition, 2024. Unpublished data. https://worldovariancancercoalition.org/our-work/ewslmic/
- Global trends and predictions in ovarian cancer mortality-PubMed. https://pubmed.ncbi.nlm.nih.gov/27597548/
Cited by
Sorted by citations
Scott, C. L., Banerjee, S. N., Joly, F., Lee, J., Mukhopadhyay, A., Tan, D. S. P., & Kohn, E. C. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00686-x · Cited by 27 · see citing works
Han, H., Hou, D., Lin, Q., Hao, X., Zhang, Z., & Peng, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1623926 · Cited by 5 · see citing works
Xu, S., Fu, X., & Wang, M. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1688767 · Cited by 5 · see citing works
Pepe, L. R., Zuccalà, V., Giordano, W. G., Giuffrè, G., Martini, M., Cianci, V., Mondello, C., Berretta, M., Cianci, S., Fiorentino, V., et al. (2026) · Cancers · doi:10.3390/cancers18081312 · Cited by 5 · see citing works
A Robust Framework for Domain-Generalized Classification of Ovarian Cancer Histology Images
Ahmed, A., & Zeng, X. (2025) · Diagnostics · doi:10.3390/diagnostics15232954 · Cited by 3 · see citing works
Shtepliuk, I., Meng, L., Borgfeldt, C., Eriksson, J., & Puglisi, D. (2026) · Advanced Intelligent Systems · doi:10.1002/aisy.202500838 · Cited by 3 · see citing works
Fathi, A., Heidari, M., Rasouli, J., & Ghasemnejad‐Berenji, H. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03766-4 · Cited by 3 · see citing works
Gao, L., Das, N., Mudiyanselage, S. B., Winter, N., Cowdery, S., White, V., & Livingston, P. M. (2026) · Cancer Medicine · doi:10.1002/cam4.71657 · Cited by 2 · see citing works
Lai, S., Lai, S., Xu, X., Huang, W., Chen, Q., He, S., & Xue, H. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02109-7 · Cited by 2 · see citing works
Shaw, P., Bhowmik, A. D., Jaswal, A. P., Velayutham, R., Chiliveru, S., Ricketts, S. D., Xu, C., Dhanasekaran, D. N., Zhao, Z. J., Bhattacharya, R., et al. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00808-x · Cited by 1 · see citing works
Allman, G., Morrell, L., Meheus, F., Ilbawi, A., Soerjomataram, I., MacKay, C., Reid, F., & Euripides, M. (2026) · JCO Global Oncology · doi:10.1200/go-26-00129
Self-citationFrom CMV to cancer : the immunological power of adaptive NK cells
Almazán, N. M. (2025) · doi:10.69622/28458692
Zou, Q., Kong, X., Zhao, Y. Y., Huo, J., Li, Y., Meng, Y., & Kang, F. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5383898
Wang, X., Zhang, Y., Xie, W., Liu, H., Cui, L., & Feng, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1659897
Barbosa, S. L. M., Porto, J. C. S., Pereira, J. C., Filho, J. I. A. B., Silva, F. P.-D., Sousa, J. M. D. C. E., Ferreira, J. R. D. O., Militão, G. C. G., & Ferreira, P. M. P. (2026) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2026.2664722
Polyploid giant cancer cells: the hidden players in ovarian cancer progression and prognosis
Roy, S., Rakhshit, S., Chakraborty, S., Chakraborty, S., Jana, S., Sircar, P., & Nayak, A. (2026) · Cell Cycle · doi:10.1080/15384101.2026.2675348
Feng, X., Chen, L., Wang, R., Wang, Z., Feng, L., Zhou, Y., Zhao, J., & Fuchun, W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1910076
Lv, H., Jiang, X., Zhang, W., Kan, S., Zhang, Y., Wang, B., Peng, F., & Yu, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1877824
Systematic Review and Meta-Analysis of Labor and Productivity Outcomes Caused by Cancer
Allman, G., Morrell, L. C., Meheus, F., Ilbawi, A., Soerjomataram, I., Mackay, C., Reid, F., & Euripides, M. (2026) · JCO Global Oncology · doi:10.1200/go-26-00130
Self-citationChitoh, A. M., Yedjou, C. G., Tchakoua, I. K., Njiki, S., Noubissi, F. K., Komolafe, T. R., Komolafe, K., Odubanjo, O. V., & Tchounwou, P. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177887
Du, X., Zhao, L., Kong, F., Wang, Q., Li, L., Zheng, J., & Hao, J. (2026) · Research Square · doi:10.21203/rs.3.rs-10676260/v1
Mukhopadhyay, A., Ruddock, A., Elsebaei, M., Memon, A., Bhattacharjee, D., & on behalf of the Tumour-Macroenvironment-Resource (TMR) Global Review Group (2026) · Cancers · doi:10.3390/cancers18203299
- Authors
- Hutchinson, B., Euripides, M., Reid, F., Allman, G., Morrell, L., Spencer, G., Ilbawi, A., Meheus, F., Gaafar, H., & Casolino, R.
- Affiliations
- RTI International (US)
- World Ovarian Cancer Coalition, Toronto, Canada
- Center for Global Noncommunicable Diseases, International Development Group, RTI International, Research Triangle Park, NC
- Cancer Control, Department of Noncommunicable Diseases, Division of Universal Health Coverage (Communicable and Noncommunicable Diseases), World Health Organization, Geneva, Switzerland
- World Health Organization (CH)
- University of Chicago (US)
- ORCID
- Venue
- JCO Global Oncology
- Published
- 2025-02
- Volume
- 11
- Issue
- 11
- Pages
- e2400313-e2400313
- ISSN
- 2687-8941 (ISSN-L)
- OpenAlex
- W4407762450
- Cited by
- 21
- References
- 45
- Citations by year
- 2026: 15 · 2025: 6
- FWCI
- 19.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- JCO Global Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- AstraZeneca
- World Health Organization
- Novocure
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- ovarian cancer, socioeconomic burden, economic burden, health care costs, labor productivity loss, caregiver burden, micro-costing, cross-national comparison
- MeSH terms
- Health Expenditures, Female, Humans, Ovarian Neoplasms, Socioeconomic Factors, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
